Clinical experience with romiplostim
Twenty patients with primary immune thrombocytopenia (ITP) received romiplastim as a second line therapy, and 3 patients with secondary thrombocytopenia as off-label. Romiplostim appeared effective in 85 % of patients with both persistent and chronic primary ITP. In patients with resistant and refra...
Saved in:
| Main Authors: | G. B. Kuchma, L. K. Kozlova, Ye. Ye. Kuznetsova, S. B. Borisyuk |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/10 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01) -
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01) -
Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
by: Vikas Talreja, et al. -
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01) -
Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)